Arbab Ali S, Yocum Gene T, Rad Ali M, Khakoo Aarif Y, Fellowes Vicki, Read Elizabeth J, Frank Joseph A
Radiology Research, Henry Ford Health System, Detroit, MI 48202, USA.
NMR Biomed. 2005 Dec;18(8):553-9. doi: 10.1002/nbm.991.
Two FDA-approved agents, ferumoxides (Feridex), a suspension of superparamagnetic iron oxide (SPIO) nanoparticles and protamine sulfate, a drug used to reverse heparin anticoagulation, can be complexed and used to label cells magnetically ex vivo. Labeling stem cells with ferumoxides-protamine sulfate (FePro) complexes allows for non-invasive monitoring by MRI. However, in order for stem cell trials or therapies to be effective, this labeling technique must not inhibit the ability of cells to differentiate. In this study, we examined the effect of FePro labeling on stem cell differentiation. Viability, phenotypic expression and differential capacity of FePro labeled CD34 + hematopoietic stem cells (HSC) and mesenchymal stem cells (MSC) were compared with unlabeled control cells. Colony-forming unit (CFU) assays showed that the capacity to differentiate was equivalent for labeled and unlabeled HSC. Furthermore, labeling did not alter expression of surface phenotypic markers (CD34, CD31, CXCR4, CD20, CD3 and CD14) on HSC, as measured by flow cytometry. SDF-1-induced HSC migration and HSC differentiation to dendritic cells were also unaffected by FePro labeling. Both FePro-labeled and unlabeled MSC were cultured in chondrogenesis-inducing conditions. Alcian blue staining for proteoglycans revealed similar chondrogenic differentiation for both FePro-labeled and unlabeled cells. Furthermore, collagen X proteins, indicators of cartilage formation, were detected at similar levels in both labeled and unlabeled cell pellets. Prussian blue staining confirmed that cells in labeled pellets contained iron oxide, whereas cells in unlabeled pellets did not. It is concluded that FePro labeling does not alter the function or differentiation capacity of HSC and MSC. These data increase confidence that MRI studies of FePro-labeled HSC or MSC will provide an accurate representation of in vivo trafficking of unlabeled cells.
两种经美国食品药品监督管理局(FDA)批准的试剂,即超顺磁性氧化铁(SPIO)纳米颗粒混悬液铁氧化物(Feridex)和用于逆转肝素抗凝作用的药物硫酸鱼精蛋白,可进行复合并用于在体外对细胞进行磁性标记。用铁氧化物 - 硫酸鱼精蛋白(FePro)复合物标记干细胞可实现通过磁共振成像(MRI)进行非侵入性监测。然而,为了使干细胞试验或治疗有效,这种标记技术不能抑制细胞分化的能力。在本研究中,我们检测了FePro标记对干细胞分化的影响。将FePro标记的CD34 +造血干细胞(HSC)和间充质干细胞(MSC)的活力、表型表达及分化能力与未标记的对照细胞进行了比较。集落形成单位(CFU)分析表明,标记的和未标记的HSC的分化能力相当。此外,通过流式细胞术检测发现,标记并未改变HSC表面表型标志物(CD34、CD31、CXCR4、CD20、CD3和CD14)的表达。FePro标记也未影响基质细胞衍生因子 - 1(SDF - 1)诱导的HSC迁移以及HSC向树突状细胞的分化。将FePro标记的和未标记的MSC都在软骨生成诱导条件下培养。对蛋白聚糖进行阿尔新蓝染色显示,FePro标记的和未标记的细胞软骨分化相似。此外,在标记和未标记的细胞团块中检测到的软骨形成指标胶原蛋白X蛋白水平相似。普鲁士蓝染色证实,标记团块中的细胞含有氧化铁,而未标记团块中的细胞则没有。得出的结论是,FePro标记不会改变HSC和MSC的功能或分化能力。这些数据增强了人们的信心,即对FePro标记的HSC或MSC进行MRI研究将准确反映未标记细胞在体内的运输情况。